NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $11.05 +0.39 (+3.66%) Closing price 04:00 PM EasternExtended Trading$11.12 +0.07 (+0.63%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Korro Bio alerts:Sign Up Key Stats Today's Range$10.73▼$11.5050-Day Range$9.15▼$14.3952-Week Range$5.20▼$55.89Volume143,445 shsAverage Volume194,060 shsMarket Capitalization$159.37 millionP/E RatioN/ADividend YieldN/APrice Target$16.71Consensus RatingModerate Buy Company Overview Korro Bio, Inc. is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches. Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.AI Generated. May Contain Errors. Read More Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 412th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingKorro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKorro Bio has a consensus price target of $16.71, representing about 51.3% upside from its current price of $11.05.Amount of Analyst CoverageKorro Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($5.36) to ($5.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.22% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Korro Bio has recently increased by 5.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentKorro Bio has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Korro Bio this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for KRRO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have sold 5,485.92% more of their company's stock than they have bought. Specifically, they have bought $5,512.00 in company stock and sold $307,896.00 in company stock.Percentage Held by Insiders4.80% of the stock of Korro Bio is held by insiders.Percentage Held by Institutions13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRRO Stock News HeadlinesKorro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm HoldingJune 15 at 7:29 PM | seekingalpha.comKorro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of "Moderate Buy" by AnalystsJune 13, 2026 | americanbankingnews.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.June 17 at 1:00 AM | Behind the Markets (Ad)Korro Bio Stockholders Approve Directors, Pay and AuditorJune 11, 2026 | tipranks.comOne Korro Bio Insider Raised Stake By 19% In Previous YearJune 11, 2026 | finance.yahoo.comInsider Selling: Korro Bio (NASDAQ:KRRO) CEO Sells 15,152 Shares of StockJune 3, 2026 | insidertrades.comKorro Bio (NASDAQ:KRRO) Director Jean Francois Formela Sells 2,860 SharesJune 2, 2026 | insidertrades.comAnalysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)May 30, 2026 | theglobeandmail.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $8.01 at the beginning of 2026. Since then, KRRO stock has increased by 38.0% and is now trading at $11.05. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.60) by $0.09. Korro Bio had a negative net margin of 1,834.48% and a negative trailing twelve-month return on equity of 117.86%. When did Korro Bio IPO? Korro Bio (KRRO) raised $90 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,000,000 shares at $14.00-$16.00 per share. Who are Korro Bio's major shareholders? Korro Bio's top institutional investors include Affinity Asset Advisors LLC (4.90%), ADAR1 Capital Management LLC (3.75%), Renaissance Technologies LLC (0.94%) and Kalehua Capital Management LLC (0.76%). Insiders that own company stock include Lynx1 Capital Management Lp, Enterprise Associates 17 New, Paul Edward Walker, Mohamad Makhzoumi, Rick Yang, Anthony A Jr Florence, Venture Opportunity Fund Atlas, Ram Aiyar, David L Lucchino, Loic A Vincent, Todd Chappell and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/07/2026Today6/17/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 KRRO's financial health is in the Green zone, according to TradeSmith. KRRO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year Founded2018Price Target and Rating Average Price Target for Korro Bio$16.71 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+51.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($11.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$117.26 million Net Margins-1,834.48% Pretax Margin-2,935.09% Return on Equity-117.86% Return on Assets-71.04% Debt Debt-to-Equity RatioN/A Current Ratio8.13 Quick Ratio8.13 Sales & Book Value Annual Sales$3.84 million Price / Sales41.48 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book2.02Miscellaneous Outstanding Shares14,423,000Free Float13,731,000Market Cap$159.37 million OptionableNo Data Beta3.01 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:KRRO) was last updated on 6/17/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
